BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls

Core Viewpoint - ADMA Biologics, Inc. is under investigation by Block & Leviton for potential securities law violations following a significant drop in its stock price due to a delay in filing its Form 10-K related to an ongoing audit by KPMG [1][2][4]. Group 1: Company Situation - Shares of ADMA Biologics fell over 8% in intraday trading on March 4, 2025, after the company announced a delay in filing its Form 10-K [2]. - The delay is attributed to an ongoing audit by KPMG that is focused on evaluating internal controls [2]. Group 2: Investor Actions - Investors who have lost money in ADMA Biologics are encouraged to contact Block & Leviton to explore options for recovering their losses [1][5]. - Eligibility for potential recovery includes anyone who purchased ADMA Biologics common stock and has experienced a decline in share value, regardless of whether they have sold their investment [3]. Group 3: Legal and Whistleblower Information - Block & Leviton is investigating the company for possible securities law violations and may file an action to recover losses for affected investors [4]. - Whistleblowers with non-public information about ADMA Biologics are encouraged to assist in the investigation, with potential rewards of up to 30% of any successful recovery from the SEC [6]. Group 4: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].